CELGENE CORP /DE/
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $3.54B | $2.96B | $11.23B | $2.08B | $1.73B | $6.49B |
| Operating income | $5.19B | $4.71B | $3.17B | $2.25B | $2.52B | $1.81B |
| Net income | $846.0M | $932.0M | $2.00B | $718.9M | $279.7M | $1.45B |
| Total assets | $35.48B | $30.14B | $28.09B | $27.05B | $17.34B | $13.38B |
| Total liabilities | $29.32B | $23.22B | $21.49B | $21.13B | $10.82B | $7.79B |
| Equity | $6.16B | $6.92B | $6.60B | $5.92B | $6.52B | $5.59B |
| EPS (diluted) | $1.10 | $1.15 | $2.49 | $0.86 | $0.33 | $1.68 |
| Shares out. | 752.2M | 778.0M | 781.7M | 800.6M | 406.0M | 418.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- 146.7%
- Net margin
- 23.9%
- Return on equity
- 13.7%
- Return on assets
- 2.4%
- Return on capital (ROCE)
- 16.5%
- Liabilities / assets
- 82.6%
- Debt / equity
- 4.76×
- Book value / share
- $8.19
- Revenue growth (YoY)
- 19.4%
- Net income growth (YoY)
- −9.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- 3.74safe
- Accruals / assets
- −12.2%clean
- Beneish M-Score
- -2.76normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 5 good- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Modified shareholder rightsNov 22, 2019
- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventNov 20, 2019
- Results of operationsOct 31, 2019
- Entered a material agreementAug 26, 2019
- Results of operationsJul 30, 2019
- Results of operationsApr 25, 2019
- Shareholder vote · Other material eventApr 12, 2019
- Other material eventApr 4, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.